Real world analysis of high-cut-off (HCO) hemodialysis with bortezomib-based backbone therapy in patients with multiple myeloma and acute kidney injury

BACKGROUND: In patients with multiple myeloma (MM) free light chain-induced cast nephropathy is a serious complication associated with poor survival. High-cut-off (HCO) hemodialysis can reduce the amount of serum free light chains (sFLC), but data on its impact on clinical outcome is limited and con...

Descripción completa

Detalles Bibliográficos
Autores principales: Steiner, N., Abdel Hamid, A., Kronbichler, A., Neuwirt, H., Myslivecek, M., Kollar, M., Lachmanova, J., Rysava, R., Hruskova, Z., Spicka, I., Willenbacher, W., Nachbaur, D., Wolf, D., Tesar, V., Gunsilius, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357738/
https://www.ncbi.nlm.nih.gov/pubmed/33382447
http://dx.doi.org/10.1007/s40620-020-00939-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357738/
https://www.ncbi.nlm.nih.gov/pubmed/33382447
http://dx.doi.org/10.1007/s40620-020-00939-2

Ejemplares similares